Shenzhen Life Biotechnology

Shenzhen Life-Bio Technology is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the development of innovative cell therapies for cancer. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) and TCR-T technologies to treat both hematological malignancies and solid tumors. Its lead programs include CAR-T therapies targeting CD19 for lymphomas and GPC3 for hepatocellular carcinoma. Shenzhen Life-Bio aims to address unmet medical needs through its proprietary cell engineering platforms and clinical research collaborations. The company maintains a robust R&D infrastructure and is actively advancing multiple candidates through early-phase clinical trials in China.